The estimated Net Worth of Yutaka Kobayashi is at least 49 千$ dollars as of 15 May 2017. Yutaka Kobayashi owns over 1,000 units of Medicinova Inc stock worth over 49,000$ and over the last 11 years Yutaka sold MNOV stock worth over 0$.
Sign up
Yutaka Kobayashi MNOV stock SEC Form 4 insiders trading
Yutaka has made over 14 trades of the Medicinova Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Yutaka bought 1,000 units of MNOV stock worth 5,600$ on 15 May 2017.
The largest trade Yutaka's ever made was buying 24,000 units of Medicinova Inc stock on 12 May 2017 worth over 134,880$. On average, Yutaka trades about 7,943 units every 47 days since 2013. As of 15 May 2017 Yutaka still owns at least 25,000 units of Medicinova Inc stock.
You can see the complete history of Yutaka Kobayashi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Yutaka Kobayashi's mailing address?
Yutaka's mailing address filed with the SEC is C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA, CA, 92037.
Insiders trading at Medicinova Inc
Over the last 17 years, insiders at Medicinova Inc have traded over 200,908$ worth of Medicinova Inc stock and bought 459,744 units worth 1,581,779$ . The most active insiders traders include Jeff Himawan、Masatsune Okajima、Yuichi Iwaki. On average, Medicinova Inc executives and independent directors trade stock every 95 days with the average trade being worth of 74,094$. The most recent stock trade was executed by Hideki Nagao on 28 November 2022, trading 6,754 units of MNOV stock currently worth 15,197$.
What does Medicinova Inc's logo look like?
Complete history of Yutaka Kobayashi stock trades at Medicinova Inc
Medicinova Inc executives and stock owners
Medicinova Inc executives and other stock owners filed with the SEC include:
-
Yuichi Iwaki,
President, Chief Executive Officer, Director -
Kazuko Matsuda,
Chief Medical Officer, Director -
Geoffrey O'brien,
Vice President -
Dr. Yuichi Iwaki M.D., Ph.D.,
Co-Founder, Pres, CEO & Exec. Director -
Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D.,
Chief Medical Officer & Director -
Hideki Nagao,
Independent Director -
Carolyn Beaver,
Director -
Edward Stepanow,
Chief Financial Officer -
Jeffrey Himawan,
Independent Chairman of the Board -
John O'Neil CPA,
Controller -
Dr. David H. Crean Ph.D.,
Chief Bus. Officer -
Dr. Federico Gaeta Ph.D.,
Chief Scientific Officer -
Douglas G Paulin CPA, CPA,
Chief Financial Officer -
Yutaka Kobayashi,
Director -
Yoshio Ishizaka,
Director -
Masatsune Okajima,
VP and Head of Japanese Office -
Federico C.A. Gaeta,
Chief Scientific Officer -
Tatsuo Izumi,
Director -
Den Boom Esther Van,
Chief Financial Officer -
Jeff Himawan,
Director -
John K A Prendergast,
Director -
Hiroaki Shigeta,
Director -
Kirk William Johnson,
Chief Scientific Officer -
Arlene Morris,
Director -
Michael Denis Coffee,
Chief Business Officer -
David D O'toole,
Director -
Alan W Dunton,
Director -
Shintaro Asako,
VP and Chief Financial Officer -
Richard E Sr Gammans,
Chief Development Officer -
Daniel Vapnek,
Director -
Kenneth W Locke,
Chief Scientific Officer -
Michael E Kalafer,
Chief Medical Officer -
Nicole Lemerond,
Director